Safety monitoring for GLP-1 therapy itself includes: Assessment for gastrointestinal adverse effects, which are common but usually transient Monitoring for signs of pancreatitis (severe, persistent abdominal pain) Vigilance for symptoms suggesting thyroid masses (neck lump, difficulty swallowing, persistent hoarseness) Regular review of glycaemic control in diabetic patients Blood pressure and cardiovascular risk factor assessment Monitoring for gallbladder disease (right upper abdominal pain, fever, jaundice) Eye examinations for people with diabetes, particularly those with pre-existing diabetic retinopathy Renal function checks, especially if experiencing severe gastrointestinal symptoms that could lead to dehydration If you have diabetes and take insulin or sulfonylureas, your doctor may reduce these doses when starting GLP-1 therapy to prevent hypoglycaemia
MMWR Morb Mortal Wkly Rep 1982;31:289-90
Evidence behind the GLP-1 class Any credible GLP-1 program rests on the pharmacology of its underlying compounds GLP-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide, plus the GIP/GLP-1 dual agonist tirzepatide
States will announce participation decisions in mid-2026
For a more visual guide on lab techniques and peptide science, we often break these topics down on our YouTube channel, which can be a great resource for researchers looking to refine their protocols
Achieve Health and Weight Loss is another company that is run by Dr